Development of inhibitoin of intimal hyperplasia after bypass operation using siRNA mTOR

Research Project

Project/Area Number	21791245
Research Category	Grant-in-Aid for Young Scientists (B)
Allocation Type	Single-year Grants
Research Field	General surgery
Research Institution	University of Yamanashi
Principal Investigator	SAKAKIBARA Kenji University of Yamanashi, 医学部附属病院, 助教 (40419338)
Project Period (FY)	2009 – 2010
Project Status	Completed (Fiscal Year 2010)
Budget Amount *help	¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000) Fiscal Year 2010: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000) Fiscal Year 2009: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Keywords	内膜肥厚 / siRNA / 大伏在静脈
Research Abstract	Rapamycin(sirolimus), initially developed as antibiotic and then as an immunosuppressant, has recently been used in drug-eluting stents to prevent restenosis. Rapamycin's cellular effects appear to be mediated through the intracellular protein target of rapamycin (TOR). The inhibitory effect of rapamycin on vascular smooth muscle cell proliferation has been well established. We examined whether the siRNA mTOR affects proliferation. siRNA mTOR decreased proliferation in vascular smooth muscle cells. siRNA mTOR could inhibit intimal hyperplasia.